Marcus Laird Forrest

US Patent:

20060251710, Nov 9, 2006

Filed:

Apr 12, 2006

Appl. No.:

11/402639

Inventors:

Glen Kwon - Waunakee WI, US
Marcus Forrest - Middleton WI, US

International Classification:

A61K 31/4745
A61K 31/395
A61K 31/337
A61K 9/127

US Classification:

424450000, 514183000, 514449000, 514291000

Abstract:

Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration.

US Patent:

20120309780, Dec 6, 2012

Filed:

Apr 30, 2012

Appl. No.:

13/460366

Inventors:

Glen S. Kwon - Waunakee WI, US
Marcus L. Forrest - Middleton WI, US

Assignee:

WISCONSIN ALUMNI RESEARCH FOUNDATION - Madison WI

International Classification:

A61K 31/436
A61K 31/395
A61K 31/337

US Classification:

514291, 514449, 514183

Abstract:

Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration.

US Patent:

20160279108, Sep 29, 2016

Filed:

Feb 24, 2016

Appl. No.:

15/052302

Inventors:

MARCUS LAIRD FORREST - LAWRENCE KS, US
TI ZHANG - LAWRENCE KS, US
S P SANJEEWA N. SENADHEERA - LAWRENCE KS, US
DANIEL AIRES - MISSION HILLS KS, US
YUNQI ZHAO - CHENGGONG, CN
SHAOFENG DUAN - LAWRENCE KS, US
CHAD GROER - LAWRENCE KS, US

Assignee:

UNIVERSITY OF KANSAS - LAWRENCE KS
NANOPHARM LLC (d/b/a HYLAPHARM) - LAWRENCE KS

International Classification:

A61K 31/436
A61K 47/48

Abstract:

The present invention is directed to drug conjugates of mTOR inhibitors comprising an mTOR inhibitor, such as rapamycin, conjugated to hyaluronic acid by a linker comprising an ester, carbonate, or carbamate. The present invention is also directed to pharmaceutical compositions comprising the drug conjugates, and methods of making and using the drug conjugates and the pharmaceutical compositions.